KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Operating Expenses: 2009-2024

Historic Operating Expenses for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to $931.1 million.

  • Novavax's Operating Expenses rose 13.70% to $248.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $757.2 million, marking a year-over-year decrease of 36.19%. This contributed to the annual value of $931.1 million for FY2024, which is 39.94% down from last year.
  • Per Novavax's latest filing, its Operating Expenses stood at $931.1 million for FY2024, which was down 39.94% from $1.6 billion recorded in FY2023.
  • In the past 5 years, Novavax's Operating Expenses registered a high of $2.8 billion during FY2021, and its lowest value of $892.3 million during FY2020.
  • Over the past 3 years, Novavax's median Operating Expenses value was $1.6 billion (recorded in 2023), while the average stood at $1.7 billion.
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 540.83% in 2020, then plummeted by 40.98% in 2023.
  • Novavax's Operating Expenses (Yearly) stood at $892.3 million in 2020, then surged by 217.47% to $2.8 billion in 2021, then fell by 7.28% to $2.6 billion in 2022, then slumped by 40.98% to $1.6 billion in 2023, then plummeted by 39.94% to $931.1 million in 2024.